Showing 2811-2820 of 5621 results for "".
- Bausch + Lomb Announces Exclusive Agreement with Modulight to Develop New Photodynamic Laserhttps://modernod.com/news/bausch-lomb-announces-exclusive-agreement-with-modulight-to-develop-new-photodynamic-laser/2476166/Bausch + Lomb and Modulight, a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new laser specifically designed for use with Bausch + Lomb’s Visudyne (verteporfin for injection)
- Ocular Therapeutix Announces FDA Approval of Dextenza for the Treatment of Ocular Pain Following Ophthalmic Surgeryhttps://modernod.com/news/ocular-therapeutix-announces-fda-approval-of-dextenza-for-the-treatment-of-ocular-pain-following-ophthalmic-surgery/2476171/Ocular Therapeutix announced that the FDA has approved Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert delivering dexamethasone to treat post-
- FDA Revamping Clearance Procedures for Medical Deviceshttps://modernod.com/news/fda-revamping-clearance-procedures-for-medical-devices/2479649/The FDA is significantly revamping the way it clears most medical devices for U.S. marketing, planning to rely far less on comparisons with much older products already on the market, according to a
- 4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-fda-orphan-drug-designation-granted-to-4d-110-for-the-treatment-of-choroideremia/2479659/Gene therapy company 4D Molecular Therapeutics (4DMT) announced that the FDA has granted orphan drug designation to 4D-110 for the treatment of choroideremia. Choroideremia (CHM) is an X-linked monogenic recessive disease (caused by mutation of the REP-1 gene) starting with reduced night v
- Santen Expands Research and Development Leadership Teamhttps://modernod.com/news/santen-expands-research-and-development-leadership-team/2479666/Santen announced the expansion of its research and development leadership team through the addition of two new executive hires. Reza M. Haque, MD, PhD, has been appointed as Senior Vice President, Global Research and Development Strategy, and Peter Sallstig, MD, MBA
- Johnson & Johnson Vision Announce $26.35 Million Collaboration for Prevention and Treatment of Myopiahttps://modernod.com/news/johnson-johnson-vision-announce-26-35-million-collaboration-for-prevention-and-treatment-of-myopia/2479677/The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI), and Johnson & Johnson Vision announced a $26.35 million research collaboration to tackle myopia. By 2050, half of the world’s population are projected to be myopic, with one billion expected to have high my
- Takeda, Shire Shareholders to Vote on Merger Deal Next Monthhttps://modernod.com/news/takeda-shire-shareholders-to-vote-on-merger-deal-next-month/2479678/Takeda and Shire announced that shareholders will vote on December 5 on the companies’ proposed $62-billion merger, with the Japanese drugmaker targeting January 8, 2019 for closing of the deal. Takeda CEO Christophe Weber remarked “with the date of our extraordinary general meeting (
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-assignment-of-permanent-j-code-for-dexycu-by-the-center-for-medicare-and-medicaid-services-cms/2479679/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is the first and only
- RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disordershttps://modernod.com/news/retipharma-secures-funding-to-develop-treatments-of-degenerative-eye-disorders/2479680/RetiPharma has announced that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be used to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds usi
- Study Demonstrates Galimedix Therapeutics’ MRZ-99030 Eye Drops Neutralize the Reproduction of Misfolded Amyloid-Betahttps://modernod.com/news/new-in-vitro-study-demonstrates-galimedix-therapeutics-investigational-compound-mrz-99030-eye-drops-neutralizes-the-reproduction-of-misfolded-amyloid-beta/2479684/Galimedix Therapeutics announced the results of a new study at the Society for Neuroscience conference demonstrating that a single application of the investigational compound MRZ-99030, also known as GAL-101, causes sustained prevention of misfolded amyloid beta molecules from aggregating into to